Menveo® is a quadrivalent meningococcal conjugate vaccine designed to protect against invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Approved for use in infants as young as 2 months and through 55 years of age, it’s ideal for pediatric immunizations, high-risk populations, and pre-college or military vaccinations.
Key Features
-
Covers 4 Meningococcal Serogroups (A, C, Y, W-135)
-
Conjugated to CRM<sub>197</sub> – a non-toxic mutant of diphtheria toxin to enhance immunogenicity
-
Flexible age range: For use from 2 months to 55 years
-
Reconstitution required: Two-component vaccine (Liquid Component + Lyophilized Powder
Product Details
-
NDC: 58160-955-09
-
Presentation: 5-dose carton
-
5 vials of MenCYW-135 Liquid Conjugate Component (Vial 1)
-
5 vials of MenA Lyophilized Component (Vial 2)
-
Dose: 0.5 mL per injection (after reconstitution)
-
Route: Intramuscular (IM) injection